中华麻醉学杂志
中華痳醉學雜誌
중화마취학잡지
CHINESE JOURNAL OF ANESTHESIOLOGY
2012年
3期
274-277
,共4页
喻文立%翁亦齐%石屹崴%王永旺%王刚%刘云霞%李津源%杜洪印
喻文立%翁亦齊%石屹崴%王永旺%王剛%劉雲霞%李津源%杜洪印
유문립%옹역제%석흘외%왕영왕%왕강%류운하%리진원%두홍인
胰蛋白酶抑制剂%心肌再灌注损伤%活体供者%肝移植
胰蛋白酶抑製劑%心肌再灌註損傷%活體供者%肝移植
이단백매억제제%심기재관주손상%활체공자%간이식
Trypsin inhibitor%Myocardial reperfusion injury%Living donor%Liver transplantation
目的 评价乌司他丁对活体肝移植术患者心肌损伤的影响.方法 择期活体肝移植术患者40例,年龄40~64岁,体重指数18 ~ 25 kg/m2,AHA心功能分级A或B级,采用随机数字表法,将其随机分为2组(n=20):对照组(C组)和乌司他丁组(U组).U组于麻醉诱导后30 min内静脉输注乌司他丁300 000 IU(溶于100 ml生理盐水),每4h重复静脉输注300000 IU,直至术毕.于切皮前即刻(T0)、无肝期30 min(T1)、新肝期30 min(T2)、术毕(T3)、术后4 h(T4)及24 h(T5)时,采集中心静脉血样,采用电化学发光免疫法分别测定血清氨基末端-脑钠肽前体(NT-proBNP)、心肌肌钙蛋白Ⅰ(cTnI)和磷酸肌酸激酶同工酶(CK-MB)的浓度.计算T1-5时血清NT-proBNP、cTnI和CK-MB浓度的变化率,记录术中心血管活性药物使用情况及心血管事件发生情况.结果 与T0时比较,两组T2-5时血清cTnI、CK-MB和NT-proBNP的浓度升高(P<0.05);与C组比较,U组T2-5时血清cTnI、CK-MB和NT-pro BNP的浓度降低(P<0.05);C组cTnI、CK-MB和NT-proBNP浓度最大变化率为4.71±1.62、6.85±1.53、4.96±1.23,U组降低为3.26+ 1.51、4.56±1.62、3.67±1.02.两组心血管不良事件发生率和多巴胺使用率比较差异无统计学意义(P>0.05).结论 静脉输注乌司他丁可在一定程度上减轻肝移植术患者心肌损伤.
目的 評價烏司他丁對活體肝移植術患者心肌損傷的影響.方法 擇期活體肝移植術患者40例,年齡40~64歲,體重指數18 ~ 25 kg/m2,AHA心功能分級A或B級,採用隨機數字錶法,將其隨機分為2組(n=20):對照組(C組)和烏司他丁組(U組).U組于痳醉誘導後30 min內靜脈輸註烏司他丁300 000 IU(溶于100 ml生理鹽水),每4h重複靜脈輸註300000 IU,直至術畢.于切皮前即刻(T0)、無肝期30 min(T1)、新肝期30 min(T2)、術畢(T3)、術後4 h(T4)及24 h(T5)時,採集中心靜脈血樣,採用電化學髮光免疫法分彆測定血清氨基末耑-腦鈉肽前體(NT-proBNP)、心肌肌鈣蛋白Ⅰ(cTnI)和燐痠肌痠激酶同工酶(CK-MB)的濃度.計算T1-5時血清NT-proBNP、cTnI和CK-MB濃度的變化率,記錄術中心血管活性藥物使用情況及心血管事件髮生情況.結果 與T0時比較,兩組T2-5時血清cTnI、CK-MB和NT-proBNP的濃度升高(P<0.05);與C組比較,U組T2-5時血清cTnI、CK-MB和NT-pro BNP的濃度降低(P<0.05);C組cTnI、CK-MB和NT-proBNP濃度最大變化率為4.71±1.62、6.85±1.53、4.96±1.23,U組降低為3.26+ 1.51、4.56±1.62、3.67±1.02.兩組心血管不良事件髮生率和多巴胺使用率比較差異無統計學意義(P>0.05).結論 靜脈輸註烏司他丁可在一定程度上減輕肝移植術患者心肌損傷.
목적 평개오사타정대활체간이식술환자심기손상적영향.방법 택기활체간이식술환자40례,년령40~64세,체중지수18 ~ 25 kg/m2,AHA심공능분급A혹B급,채용수궤수자표법,장기수궤분위2조(n=20):대조조(C조)화오사타정조(U조).U조우마취유도후30 min내정맥수주오사타정300 000 IU(용우100 ml생리염수),매4h중복정맥수주300000 IU,직지술필.우절피전즉각(T0)、무간기30 min(T1)、신간기30 min(T2)、술필(T3)、술후4 h(T4)급24 h(T5)시,채집중심정맥혈양,채용전화학발광면역법분별측정혈청안기말단-뇌납태전체(NT-proBNP)、심기기개단백Ⅰ(cTnI)화린산기산격매동공매(CK-MB)적농도.계산T1-5시혈청NT-proBNP、cTnI화CK-MB농도적변화솔,기록술중심혈관활성약물사용정황급심혈관사건발생정황.결과 여T0시비교,량조T2-5시혈청cTnI、CK-MB화NT-proBNP적농도승고(P<0.05);여C조비교,U조T2-5시혈청cTnI、CK-MB화NT-pro BNP적농도강저(P<0.05);C조cTnI、CK-MB화NT-proBNP농도최대변화솔위4.71±1.62、6.85±1.53、4.96±1.23,U조강저위3.26+ 1.51、4.56±1.62、3.67±1.02.량조심혈관불량사건발생솔화다파알사용솔비교차이무통계학의의(P>0.05).결론 정맥수주오사타정가재일정정도상감경간이식술환자심기손상.
Objective To investigate the effects of ulinastatin on the myocardial injury in patients undergoing live donor liver transplantation.Methods Forty patients (AHA classification grade A or B),aged 40-64 yr,with a body mass index of 18-25 kg/m2,scheduled for live donor liver transplantation,were randomly divided into 2 groups ( n =20 each):control group (group C) and ulinastatin group (group U).Anesthesia was induced with midazolam,sufentanil,and cisatracurium besilate.The patients were tracheal intubated and mechanically ventilated.Ulinastatin 300 000 IU in 100 ml of normal saline was infused intravenously over 30 min after anesthesia induction and then the infusion was repeated at 4 h interval until the end of operation in group U,while the equal volume of normal saline was given in group C.Blood samples were taken from the central vein immediately before skin incision (T0,baseline),at 30 min of anhepatic phase (T1),at 30 min of neohepatic phase (T2),and at 0,4 and 24 h after operation (T3-5) for determination of the concentrations of serum cardiac troponin Ⅰ (cTnI),creatine kinase-MB (CK-MB) and N-terminal pro-brain natriuretic peptide (NT-proBNP).The changing rates of cTnI and CK-MB at T1-5 were calculated.The use of cardiovascular drugs and cardiovsscular accidents were recorded during operation.Results The serum cTnI,CK-MB and NT-proBNP concentrations were significantly higher at T2-5 than at T0 in the two groups ( P < 0.05).Compared with group C,the serum cTnI,CK- MB and NT-proBNP concentrations at T2-5 were significantly deceased in group U ( P < 0.05).The maximal changing rates of cTnI,CK-MB and NT-proBNP concentrations were 4.71 ± 1.62,6.85 ± 1.53 and 4.96 ± 1.23 respectively in group C,decreased to 3.26 ± 1.51,4.56 ± 1.62 and 3.67 ± 1.02 respectively in group U.There was no significant difference in the incidence of cardiovascular accidents and the use of dopamine between the two groups.Conclusion Intravenous infusion of ulinastatin can attenuate the myocardial injury to some extent in patients undergoing live donor liver transplantation.